Tizanidine Tablet
Product Images NDC 76420-866

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Tizanidine (NDC 76420-866). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Asclemed Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Container1 (Container1)

Packaging labels for Tizanidine Tablets USP 2 mg, manufactured by Enovachem Pharmaceuticals and packaged by Northstar Rx LLC, Torrance, CA. Labels show various package quantities: 30, 60, 90, 120, and 150 tablets. Each label includes the NDC number, lot, expiration, drug status RX, and storage instructions at controlled room temperature.*

FDA Label Image

Container2 (Container2)

Packaging labels for Tizanidine Tablets USP 4 mg by Enovachem Pharmaceuticals. Labels indicate multiple package quantities: 30, 60, 90, 120, 150, and 1000 tablets. Each label includes details such as the NDC number, manufacturing and relabeling information, and storage instructions, with a consistent design featuring the Enovachem logo and QR codes.*

FDA Label Image

Fig1 (Fig1)

A line graph depicting plasma tizanidine concentration (ng/mL) over time (hours) following dosing. The chart compares four conditions: 2 x 4 mg tizanidine tablets with food, tablets without food, capsules with food, and capsules without food, showing concentration changes across 24 hours after dosing.*

FDA Label Image

Fig2 (Fig2)

A line graph showing improvement in Ashworth Score over 6 hours post-dose for three groups: 16 mg tizanidine, 8 mg tizanidine, and placebo. The vertical axis measures improvement, with higher values indicating greater improvement, while the horizontal axis represents hours post-dose from 0 to 6. The graph includes error bars for each time point.*

FDA Label Image

Fig3 (Fig3)

A line graph comparing improvement in Ashworth Score between tizanidine (mean dose 28.8 mg) and placebo over three time points: End of Titration (Study Week 3), End of Maintenance (Study Week 7), and Endpoint (Last Observation Carried Forward). Tizanidine shows greater improvement than placebo at all points with error bars indicating variability.*

FDA Label Image

Structure (Structure)

Chemical structure of Tizanidine hydrochloride shown as a two-ring system with nitrogen atoms, reflecting its molecular composition as an oral tablet drug ingredient.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.